Two of the 77 patients pursued genetic testing due to cascade testing for an LPV/PV in a non-PGL/PCC gene, and because they underwent pan-cancer panel testing, were identified to have an SDHA and an NF1 LPV/PV, respectively. This evidence concerns the gene NF1 and cancer.